Introduction
============

*Lippia alba* (Mill.) N.E. Brown Verbenaceae (LA) is an aromatic shrub, widely used in Central and South America for the treatment of different clinical conditions such as digestive, respiratory and cardiovascular disorders and as an antiseptic, analgesic and tranquilizer ([@B01]).

The results of experimental studies conducted with LA are generally consistent with its traditional uses. Thus, antibacterial and antifungal activities have been shown for different root and leaf extracts ([@B02],[@B03]) and antiviral activity was observed with an ethanol leaf extract ([@B04]). Also anxiolytic effects in the elevated plus-maze have been previously shown after acute *ip* administration to mice of essential oils (EOs) from two different chemotypes of LA ([@B05]) (chemotype I, two subtypes, i.e., subtype 1: 55% citral, 10% β-myrcene and subtype 2: 64% citral, 12% limonene; chemotype II: 55% carvone, 23% limonene; doses ranging from 25-200 mg/kg) ([@B06]).

However, tests with some of the isolated constituents (citral, myrcene and limonene, 25-200 mg/kg, *ip*) of the three EOs showed inconsistent results. Although these constituents exhibited sedative activity when administered acutely to rats (muscle relaxation in the rota-rod, decreases in the number of rearings and groomings in the open-field, and potentiation of pentobarbital-induced sleeping time), they did not exhibit an anxiolytic effect in the elevated plus-maze, but rather a slight anxiogenic effect at higher doses ([@B07]). This inconsistency questions the relevance of any conclusion concerning the anxiolytic properties of LA ([@B01]). Therefore, further investigations on the plant\'s use as a tranquilizer are still warranted.

In this respect, it should be pointed out that, although important as a first step for the evaluation of the anxiolytic properties of LA, the above studies ([@B06],[@B07]) were performed with a single animal model, the elevated plus-maze. Even though the model is widely used, it has failed to detect the effect of non-benzodiazepine anxiolytics ([@B08],[@B09]). Some investigators have suggested that this may occur because the elevated plus-maze is a "mixed" animal model, that is, one that does not separate different types of fear/anxiety ([@B08]). According to the DSM-IV-TR classification of psychiatric disorders, clinical anxiety is a heterogeneous phenomenon, comprising distinctive pathological conditions, such as generalized anxiety disorder (GAD), panic and phobias - these conditions being unequally affected by pharmacological therapy. On this basis, there is a growing body of evidence suggesting that anxiety, as operationally defined in a given animal model, may differ from that generated in other models concerning its nature (if innate or learned), its response to the effects of drugs and environmental manipulations, and its underlying neural substrate ([@B10]). On the basis of this evidence, efforts have been made to validate experimental models specifically related to certain kinds of anxiety disorders ([@B10]). A model that measures behavioral responses particularly related to specific subtypes of anxiety is the elevated T-maze (ETM) ([@B11]-[@B14]).

Although derived from the elevated plus-maze, the ETM allows the measurement of two subtypes of anxiety-related responses in the same rat, i.e., inhibitory avoidance and one-way escape. Compounds representative of three classes of anxiolytics, namely the agonist of benzodiazepine receptors diazepam (DZP), the serotonin (5-HT) 1A agonist buspirone, and the nonselective 5-HT2 antagonist ritanserin, have been shown to selectively impair inhibitory avoidance while leaving one-way escape unchanged ([@B11],[@B12]). These results are compatible with the view that inhibitory avoidance is related to GAD. In contrast, the escape task is insensitive to different classes of anxiolytics and is impaired by chronic, but not acute administration of imipramine ([@B13]), clomipramine and fluoxetine ([@B14]), drugs that are used to treat panic disorder. As a result, one-way escape in the ETM has been used as an animal model of panic.

The purpose of the present study was to further investigate the anxiolytic properties of LA by using the ETM, a model that allows the measurement of two different anxiety-related responses, one associated with GAD and the other with panic disorder. Since some pharmacological compounds have been shown to ameliorate specific subtypes of anxiety disorders (or to alter particular types of behavioral responses) only after repeated treatment ([@B13]-[@B15]), this regimen of administration was chosen. In the present study, male Wistar rats were treated daily for 14 days (12.5 and 25 mg/kg, *ip*) with chemotype II, and subsequently tested in the ETM (experiment 1). We also determined the effects of repeated treatment with (R)-(-)-carvone, one of the main constituents of this chemotype, on the behavior of animals tested in the ETM (experiment 2). Among the main constituents of the three EOs previously investigated ([@B06]), carvone was the only one not tested for anxiolysis. For both experiments, DZP was used as a positive control. In order to avoid confounding results due to treatment effects on locomotor activity, animals were also tested in an open field.

Material and Methods
====================

Animals
-------

Male Wistar rats (approximately 250 g) bred in the animal house of Universidade de São Paulo, Ribeirão Preto Campus (experiment 1), or of Universidade Federal de São Paulo, Brazil (experiment 2), were housed 5-6 per cage until the ETM experiments. Room temperature was controlled (23 ± 1°C) and lights were kept on from 7:00 am to 7:00 pm. Food and water were available *ad libitum*. The present study was approved by the Ethics Committee for Animal Research of Universidade Federal de São Paulo (protocol No. 0252/11) and was performed in compliance with the recommendations of the Brazilian Society of Neuroscience and Behavior (SBNec), which are based on the US National Institutes of Health Guide for Care and Use of Laboratory Animals.

Plant material
--------------

LA was cultivated in the Medicinal Plant Garden and an exsiccate deposited in the Prisco Bezerra Herbarium of Universidade Federal do Ceará under No. 24.149. EO samples from the leaves of chemotype II were prepared by the Laboratory of Natural Products of the University.

Essential oil
-------------

Leaves (1 kg) from chemotype II were collected on the same day and at the same time from flowering plants. Samples were steam distilled for 1 h. The EO was analyzed by GC:MS using a Hewlett-Packard 5971 instrument under the following conditions: column, dimethylpolysiloxane DB-1 fused-silica capillary column (30 m_0.25 mm); carrier gas, helium (1 mL:min); injector temperature, 35-180°C at 4°C:min, then 180-250°C at 10°C:min; mass spectrum electron impact, 70 eV. Individual components were identified by spectrometric analysis using two computer library MS searches, and Kovats indices as a preselection aid. Visual mass spectrum comparison data from the literature were used for confirmation.

Compound preparations
---------------------

EO from chemotype II, (R)-(-)-carvone (Sigma, USA) and DZP (Sigma) were suspended in saline with 2% Tween 80. Control animals were injected with a vehicle solution (saline containing 2% Tween 80). All compounds were prepared on the same day of the experiments and administered intraperitoneally (*ip*) in a volume of 1 mL/kg body weight. The doses administered in experiments 1 and 2 were chosen on the basis of pilot studies conducted in our laboratory, taking into account previously published data ([@B05],[@B16]).

Apparatus
---------

*Elevated T-maze*. The ETM was made of wood and had 3 arms of equal dimensions (50 × 12 cm). One arm was enclosed by 40-cm high walls and was arranged perpendicularly to two opposed open arms. The entire apparatus was elevated 50 cm above the floor. To avoid falls, the open arms were surrounded by a Plexiglas rim 1 cm high.

*Open field*. For experiment 1, the apparatus used to measure locomotion was a square wooden box (60 × 60 cm), with the floor divided into 9 equal parts, and walls 30 cm high.

For experiment 2, the apparatus used was a round arena (60 × 60 cm), with the floor divided into 16 parts, and walls 50 cm high.

Luminosity at the level of the maze arms or the open field center was 60 lux. After each experimental session, the models were cleaned with a 10% ethanol solution.

Procedure
---------

Animals were injected *ip* with the EO from chemotype II (12.5 and 25 mg/kg), (R)-(-)-carvone (25 mg/kg), DZP (2 mg/kg), or vehicle daily for 14 consecutive days. On the 13th day, each animal was pre-exposed to one of the open arms of the ETM for 30 min immediately before treatment. It has been shown that pre-exposure shortens escape latencies on the test day, rendering the escape test more sensitive to the effects of treatment ([@B17]). On the following day, 30 min after treatment, each animal was placed at the distal end of the enclosed arm of the ETM facing the intersection of the arms. The time taken by the rat to leave this arm, with all four paws, was recorded (baseline latency). Avoidance 1 and 2 were measured in the same way as baseline latency at 30-s intervals, during which animals were placed in a Plexiglas cage to which they had been previously habituated. Following avoidance training (30 s), rats were placed at the end of one of the open arms of the ETM and the time taken to leave this arm with all paws was recorded for three consecutive times with 30-s intertrial intervals (escape 1, 2, and 3). Immediately after being tested in the ETM, each animal was placed for 5 min in the open field for further evaluation of locomotor activity. During this time, the total number of lines crossed and the frequency of rearings were measured.

Statistical analysis
--------------------

Repeated measures analysis of variance (ANOVA) was used to analyze avoidance and escape measurements, with treatment as the independent factor and trials as the dependent factor. In the case of significant effects of treatment or of the treatment versus trial interaction, data were analyzed by the Duncan *post hoc* test. The open field results were submitted to one-way ANOVA followed by the Duncan *post hoc* test. In all cases, a value of P ≤ 0.05 was considered to be significant.

Results
=======

[Table 1](#t01){ref-type="table"} shows the main components of chemotype II. It can be seen through CG:MS analysis that carvone accounts for approximately 55% and limonene for 23% of the composition of this chemotype.

Table 1.Constituents of chemotype II from *Lippia alba* (Mill) N.E.SubstanceRetention timeKovats indexRelative percentage (%)Alpha-thujene3.379240.28Alpha-pinene3.489280.21Sabinene4.299562.98Myrcene4.689700.46Limonene5.69100523.13Beta-ocimene (Z)6.1110200.43Gamma-terpinene6.6210380.70Terpinen-4-ol9.9011520.22Carvone12.53124454.57Isopiperitenone15.2313390.97Beta-bourbonene16.4513810.73Beta-cubebene16.6713890.26Beta-elemene16.7413910.28Caryophyllene (E)17.5214190.34Aromadendrene Allo18.8014630.26Alpha-muurolene19.5514904.84Gamma-cadinene19.9315030.24Geracrene A20.2015000.41Bulnesol21.6815642.14[^1]

Experiment 1 - Effects of chemotype II
--------------------------------------

The upper panel in [Figure 1](#f01){ref-type="fig"} shows the anxiolytic effects of treatment with chemotype II from LA and with DZP on ETM avoidance measurements. Repeated measures ANOVA showed a significant effect of treatment (F(3,25) = 3.81; P = 0.022) and treatment versus trial interaction (F(6,50) = 3.54; P = 0.005), but no effect of trials (F(2,50) = 2.39; P = 0.102). The Duncan *post hoc* test showed that all treatment groups were significantly different from the control group in avoidance 2 (P \< 0.05).

Figure 1.Effects of repeated daily treatment (14 days) with chemotype II from *Lippia alba* and with 2 mg/kg diazepam (DZP) on avoidance (upper panel) and escape measurements (lower panel) in the elevated T-maze. EO = essential oil. Control (N = 8); 12.5 mg/kg EO (N = 7); 25 mg/kg EO (N = 6); DZP (N = 8). Data are reported as means ± SEM. ^\*^P \< 0.05 compared to control (ANOVA followed by the Duncan *post hoc* test).

The lower panel in [Figure 1](#f01){ref-type="fig"} shows absence of effects of the same treatments on one-way escape in the ETM. Repeated measures ANOVA showed a significant effect of trials (F(2,50) = 9.89; P \< 0.001), but no effects of treatment (F(3,25) = 0.12; P = 0.948) or treatment versus trial interaction (F(6,50) = 0.707; P = 0.645).

One-way ANOVA showed that locomotor activity was not changed by drug administration. Neither the number of rearings (F(3,25) = 0.811; P = 0.50) nor the number of crossings (F(3,25) = 0.793; P = 0.509) were altered by treatment with chemotype II from LA or with DZP (data not shown).

Experiment 2 - Effects of (R)-(-)-carvone
-----------------------------------------

The upper panel in [Figure 2](#f02){ref-type="fig"} illustrates the anxiolytic effects of treatment with (R)-(-)-carvone and DZP on ETM avoidance measurements. Repeated measures ANOVA showed a significant effect of trials (F(2,50) = 5.43; P = 0.007), treatment (F(2,25) = 19.79; P \< 0.001) and treatment versus trial interaction (F(4,50) = 6.24; P \< 0.001). The Duncan *post hoc* test showed that (R)-(-)-carvone was significantly different from the control group in avoidance 1 and that DZP was significantly different from the control group in avoidance 1 and 2 (P \< 0.05).

Figure 2.Effects of repeated daily treatment (14 days) with (R)-(-)-carvone and with 2 mg/kg diazepam (DZP) on avoidance (upper panel) and escape measurements (lower panel) in the elevated T-maze. Control (N = 12); 25 mg/kg (R)-(-)-carvone (N = 8); DZP (N = 8). Data are reported as means ± SEM. ^\*^P \< 0.05 compared to control (ANOVA followed by the Duncan *post hoc* test).

The lower panel in [Figure 2](#f02){ref-type="fig"} shows absence of effects of the same treatments on one-way escape in the ETM. Repeated measures ANOVA showed a significant treatment versus trial interaction (F(4,50) = 2.93; P = 0.03), but no effect of trials (F(2,50) = 0.215; P = 0.81) or treatment (F(2,25) = 0.114; P = 0.89). The Duncan *post hoc* test showed that neither (R)-(-)-carvone nor DZP were significantly different from the control group in any trial.

Again, one-way ANOVA showed that locomotor activity was not changed. Neither the number of rearings (F(2,25) = 2.49; P = 0.10) nor the number of crossings (F(2,25) = 0.31; P = 0.74) were altered by treatment with (R)-(-)-carvone or with DZP (data not shown).

Discussion
==========

The results of the present study showed that repeated treatment with chemotype II from LA at the two doses administered (12.5 and 25 mg/kg, *ip*) decreased ETM avoidance latencies, an anxiolytic effect. This same result was also observed with (R)-(-)-carvone and with the reference drug DZP. Escape measurements, on the other hand, were not modified by any of the treatments administered. Since the responses measured in the open field were not altered by treatment, it is possible to state that the anxiolytic effects observed are independent of locomotor alterations.

Our results are in agreement with previous reports of anxiolytic effects after acute treatment with higher doses (100 and 200 mg/kg, *ip*) of chemotype II in another animal model of anxiety, the elevated plus-maze ([@B05]). As observed in the present study, there were no changes in the number of crossings in the open field, although the dose of 200 mg/kg altered the number of rearings, indicating a possible neurosedative action in this dose range.

Differently from the elevated plus-maze, which, as mentioned, has been considered to be a mixed animal model of anxiety ([@B08],[@B09]), the ETM allows the measurement of two behavioral defensive responses specifically related to anxiety disorders found in clinical settings. In this respect, one of the main observations of the present study was that chemotype II acted selectively on inhibitory avoidance in clinical terms related to GAD ([@B11]-[@B14]). This selective profile of action may also explain the controversial effects observed with LA ([@B06],[@B07]). For instance, it is possible that the lack of anxiolysis of some of the isolated constituents previously tested ([@B07]) reflects the lack of effect of LA on escape responses from the open arms of the plus-maze. Thus, further studies performed with different chemotypes of LA and other main constituents in more selective animal models of anxiety, in particular models that measure GAD-related responses (see Ref. 10), are still warranted.

In light of our present results, a role for carvone, the major constituent of chemotype II, was also suggested. In experiment 2, we tested the effects of repeated treatment with (R)-(-)-carvone, which in another study had shown a more potent neurosedative activity than the enantiometer (S)-(+)-carvone ([@B16]). Our results showed that (R)-(-)-carvone decreased avoidance 1 latencies in the same way as DZP, without altering escape performance. The effect of (R)-(-)-carvone seems to be weaker than that of DZP, at least at the dose administered, since the latter drug also altered avoidance 2. It is interesting to point out that an anxiolytic effect of carvone had been previously proposed by Mora et al. ([@B18]). These authors investigated the anxiolytic and neurosedative effects in different animal models of a hydroalcoholic extract of *Aloysia polystachya* (Griseb.), a plant of the Verbenaceae family that is widely distributed in subtropical regions of South America and that contains carvone as a major constituent.

In fact, previous studies have shown that carvone, a monoterpene ketone of the terpenes and the main active ingredient of essential oils used in folk medicine and in phytotherapy as sedatives or tranquilizers, acts as a potent depressor of the central nervous system ([@B16],[@B19]). For instance, Buchbauer et al. ([@B19]) showed that the inhalation of two enantiomers of carvone ((S)-(+)-carvone and (R)-(-)-carvone) decreases locomotor activity in mice. A more recent study ([@B16]) indicated that the *ip* administration of these same enantiomers causes different depressant effects in mice, such as decreases in ambulation and in the reaction to touch, palpebral ptosis, and increases in sedation. Also, both enantiomers significantly potentiated pentobarbital sleeping time and increased the latency of convulsions induced by pentylenetetrazole and picrotoxin in a way similar to the reference drug DZP ([@B16]). Taking into account the depressant effects of carvone and the proposed mechanism of action for other monoterpene compounds ([@B20]), de Sousa et al. ([@B16]) suggested that carvone possibly interacts with GABAA receptors in the brain after crossing the blood-brain barrier. In the light of our present observations, this fact makes sense. It is possible that carvone inhibits neurons, which modulate behavioral inhibition (i.e., avoidance responses) in brain areas such as the amygdala and the septo-hippocampal system, structures that are activated in approach-avoidance conflict situations ([@B10]) (such as the one present when the animal is placed in the enclosed arm of the ETM).

In conclusion, the present results showed that repeated treatment with chemotype II from LA exerts anxiolytic-like effects on a specific subtype of defensive behavior that has been related to GAD in humans. The same was observed with (R)-(-)-carvone. Thus, it is possible that carvone, the main constituent of chemotype II, is one of the plant\'s constituents responsible for its therapeutic actions on anxiety.
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[^1]: Kovats index is a logarithmic scale on which the adjusted retention time of a peak is compared with those of unbranched alkanes. The relative percentage refers to the area calculated under the peak for that specific compound with respect to the total peak area.
